Covid Vaccine Race

A phase 3 trial shows one dose is 91.7 % effective against severe disease.

A study of mRNA vaccination in older people and people with comorbidities found vaccine efficacy of 69% against COVID-19 infection and 86% against death.

The administration is going to buy 500 million at-home rapid COVID-19 tests, and make them available to Americans. They also plan to use federal resources to provide pop-up clinics and get more pharmacists involved in vaccinations.

Two different doses of the company's mRNA vaccine were found to increase antibodies by up to 83-fold.

Planning travel and social gatherings as Omicron gathers steam requires extra preparation and a degree of flexibility.

Pfizer-BioNTech will be testing 3 doses of their vaccine in children older than 6 months and younger than 5 years, instead of the original 2-dose regimen.

The CDC is recommending the Pfizer-BioNTech and Moderna COVID-19 vaccines over Janssen’s, due to 57 cases of a rare blood clotting condition.

Side effects that occur during concurrent vaccine administrations can influence future vaccine decisions.

A review of the data and circumstances that led to authorization in children ages 5 to 11 years.

Clinical trial compares immunogenicity of mixing mRNA, adenoviral and spike-adjuvant vaccines in 2-dose series against COVID-19.

A reflection on the wins and setbacks in the second year of our pandemic, 2021.

A booster dose of the m-RNA vaccine reduced COVID-19 and the rates of severe illness across adult age groups.

New cohort data from VA medical centers provide more evidence of a correlate between antibody levels and vaccine effectiveness for mRNA vaccines.

An Israeli study found that a third “booster” shot of the Pfizer-BioNTech vaccine reduced the risk of COVID-19 death by 90%.

Faced with the growing threat of the Delta and Omicron variants, the FDA authorized Pfizer-BioNTech booster doses for 16- and 17-year-olds.

Data indicate that a third dose of the Pfizer-BioNTech vaccine, BNT162b2, increases the neutralizing antibody titers by 25-fold compared to 2 doses against the Omicron variant.

A study released tonight found 6 COVID-19 booster shots increased immunity for individuals who received a full 2 doses of the AstraZeneca or Pfizer-BioNTech vaccines.

The strategies address booster doses, travel, and rapid response.

As there is a lot of information regarding the Omicron variant, here is our latest slideshow to offer some insights on it.

Moderna and Pfizer's CEOs voice doubt on the current vaccines’ efficacy with the new variant, but are developing prophylaxis vaccines and treatment strategies to curtail the new strain.

In its first real-world study, 2 doses of India’s BBV152 vaccine offered 50% protection against symptomatic COVID-19.

Routine infant, child, and adolescent vaccination rates and coverage were lower in 2020 than in 2019, particularly for Black children.

Today, the Advisory Committee on Immunization Practices (ACIP) unanimously voted the CDC should approve Pfizer-BioNTech and Moderna booster doses for all adults.

The FDA has authorized the Moderna and Pfizer-BioNTech COVID-19 booster shots for all Americans 18 and older.

AstraZeneca’s PROVENT and TACKLE stage 3 trials show its vaccine AZD7442 significantly reduced the risk of severe or fatal COVID-19, even among high-risk populations.

A new report suggests FDA and CDC deliberations may result in booster doses of the mRNA vaccine becoming available by this weekend.

Previous research suggested vaccine efficacy significantly dips after 6 months, but a new study finds COVID-19 cellular immunity remains strong.

Just 39 cases among more than 2.2 million doses administered.

2 doses of the India-developed vaccine BBV152 offer 77.8% protection against symptomatic COVID-19 disease.

Pfizer-BioNTech's request for the Emergency Use Authorization (EUA) will apply to everyone 18 years and older.